Bendazac

Summary

Bendazac (CHEMBL1089221) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC M02AA11); indicated across 3 conditions including eye disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M02AA11 (+1 more)
• Indications: 3 conditions
• Chemistry: 282.29 Da · C16H14N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1089221
Name	Bendazac
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2313
ChEBI	CHEBI:31257
ATC	M02AA11, S01BC07
Molecular formula	C16H14N2O3
Molecular weight	282.29
InChIKey	BYFMCKSPFYVMOU-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=N2)OCC(=O)O

IUPAC name: 2-(1-benzylindazol-3-yl)oxyacetic acid

ChEBI definition: A monocarboxylic acid that is glycolic acid in which the hydrogen attached to the 2-hydroxy group is replaced by a 1-benzyl-1H-indazol-3-yl group. Although it has anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties and has been used for the treatment of various inflammatory skin disorders, its principal effect is to inhibit the denaturation of proteins. Its lysine salt is used in the management of cataracts.

Pharmacological roles (ChEBI): radical scavenger, non-steroidal anti-inflammatory drug.

Also known as: AF 1934 FREE ACID, AF 1934 [LYSINE], AF-1934 FREE ACID, AF-1934 LYSINE, Bendazac, Bendazaco, Bindazac, Iwazac, SID50112715, bendazac, BENDAZAC

Parent form; salt/anhydrous children: CHEMBL1089222, CHEMBL3189046

Patent coverage: 2,446 distinct patent families (8,967 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 8,965 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
eye disorder	4	MONDO:0005328	EFO:0005752

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).